SRL
ALNY icon

Scientech Research LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

Scientech Research LLC’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-676
Closed -$269K – 463
2025
Q4 		$269K Sell
676
-3,196
-83% -$1.41M 0.17% 223
2025
Q3 		$1.77M Buy
+3,872
New +$1.58M 0.62% 6
2025
Q1 		– Sell
-2,280
Closed -$537K – 558
2024
Q4 		$537K Buy
+2,280
New +$600K 0.15% 270
2024
Q2 		– Sell
-2,688
Closed -$402K – 574
2024
Q1 		$402K Buy
+2,688
New +$448K 0.21% 216

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Scientech Research LLC's ALNY Position: Q1 2026 in Review

Scientech Research LLC sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 676 shares — an estimated $269K sold.

Scientech Research LLC first reported a position in ALNY in Q1 2024 and held it in 4 quarters. The position peaked at $1.77M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Scientech Research LLC reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Scientech Research LLC sold 676 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $269K.
  • Scientech Research LLC first reported a position in Alnylam Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Scientech Research LLC's Alnylam Pharmaceuticals position peaked at $1.77M in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Scientech Research LLC's 13F filing for Q1 2026, filed 15 May 2026.